Bradley J. Carver
Directeur Général chez SynDevRx, Inc.
Profil
Bradley J.
Carver is the founder of SynDevRx, Inc. Prior to that, he served as the President, Chief Executive Officer, and Treasurer of Glycogenesys, Inc. from 1995 to 2006.
He obtained his undergraduate degree from Michigan State University in 1983.
Postes actifs de Bradley J. Carver
| Sociétés | Poste | Début |
|---|---|---|
SynDevRx, Inc.
 SynDevRx, Inc. Miscellaneous Commercial ServicesCommercial Services SynDevRx, Inc. develops treatments for metabolic-related diseases. Its product includes SDX-7320, a polymer conjugate of fumagillol that releases a pharmacologically active small molecule fumagillol derivative in vivo. The company was founded by James M. Shanahan and Bradley J. Carver and is headquartered in Cambridge, MA. | Directeur Général | - |
Anciens postes connus de Bradley J. Carver
| Sociétés | Poste | Fin |
|---|---|---|
Glycogenesys, Inc.
 Glycogenesys, Inc. Miscellaneous Commercial ServicesCommercial Services GlycoGenesys, Inc., a biotechnology company, develops novel pharmaceutical products based on carbohydrate compounds and related technologies. The company's lead drug candidate GCS-100, a treatment for various forms of solid tumors and bloodborne cancers, completed a Phase II (a) clinical trial for pancreatic cancer, and also completed a Phase II (a) clinical trial for colorectal cancer. The company focuses on the development of carbohydrate-based pharmaceutical products and related technologies in connection with oncology. It was founded in 1992 and is headquartered in Boston, MA. | President | 31/01/2006 |
Formation de Bradley J. Carver
| Michigan State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Glycogenesys, Inc.
Glycogenesys, Inc. Miscellaneous Commercial ServicesCommercial Services GlycoGenesys, Inc., a biotechnology company, develops novel pharmaceutical products based on carbohydrate compounds and related technologies. The company's lead drug candidate GCS-100, a treatment for various forms of solid tumors and bloodborne cancers, completed a Phase II (a) clinical trial for pancreatic cancer, and also completed a Phase II (a) clinical trial for colorectal cancer. The company focuses on the development of carbohydrate-based pharmaceutical products and related technologies in connection with oncology. It was founded in 1992 and is headquartered in Boston, MA. | Commercial Services |
SynDevRx, Inc.
SynDevRx, Inc. Miscellaneous Commercial ServicesCommercial Services SynDevRx, Inc. develops treatments for metabolic-related diseases. Its product includes SDX-7320, a polymer conjugate of fumagillol that releases a pharmacologically active small molecule fumagillol derivative in vivo. The company was founded by James M. Shanahan and Bradley J. Carver and is headquartered in Cambridge, MA. | Commercial Services |